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Influence of peritoneal dialysis solutions with glucose and amino acids
on ingestive behavior in rats. Continuous ambulatory peritoneal dialysis
(CAPD) is often associated with malnutrition; reduced intake of nutrients
due to anorexia is an important factor. The glucose load from glucose-
based peritoneal dialysis (PD) solutions and amino acids from amino
acid-based solutions may favor suppression of the appetite. To study this
matter we used a new experimental model in free-moving, unstressed male
Wistar rats (300 to 350 g) with feeding catheters channeled from the top
of the skull to the oral cavity. When the rats recovered from surgery they
were tested under standardized conditions by giving them an intraoral
infusion (1 mI/mm) of a solution containing 342 glliter of the sucrose or 97
g/liter protein solutions while recording the time (volume) of ingestion.
Control rats consumed 18.8 0.9 ml of the sucrose and 39.8 0.8 ml of
the protein solutions. Injections of PD solutions with 13.6, 22.7 and 38.6
g/liter of glucose reduced the ingestion of sucrose by 12.4%, 23.6% and
36.1%, respectively, but did not affect the ingestion of protein. Injections
of 30 ml of PD solutions containing 11, 18 and 31 g/liter of amino acids
reduced the ingestion of both sucrose by 9.7%, 17.1% and 33.2% and of
protein by 13.5%, 25.9% and 33.1%, respectively. We conclude that in our
experimental model, the inhibition of appetite caused by peritoneal
solutions containing glucose or amino acids seems to be specific for each
nutritional constituent and not simply an effect of hyperosmolality or large
filling volumes.
A large proportion of patients treated with continuous ambu-
latory peritoneal dialysis (CAPD) show anthropometrie and bio-
chemical signs of malnutrition [1]. The finding that requirements
of protein in CAPD patients are higher than in healthy individuals
[2, 31, has been attributed, inter a/ia, to dialytic losses of protein
and amino acids. The nutritional intakes of protein and energy are
below the requirements [3—5J. Loss of appetite secondary to
abdominal distension by the dialyzate, absorption of glucose or
amino acids from the dialyzate and persistent uremic toxicity due
to underdialysis have been thought to result in impairment of
appetite [61. Moreover, several factors not directly linked to the
dialytic treatment, such as psychosocial problems, medications,
dietary restrictions and intercurrent illnesses, may partly account
for the low nutritional intakes.
Glucose has been used as the primary osmotic agent since
treatment with peritoneal dialysis was first started. Glucose, of
course, is not an inert osmotic agent but is also a nutrient that can
contribute as much as one third of the total energy intake,
especially in patients with high peritoneal permeability [7]. There
is, however, concern about the effects of chronic glucose exposure
on the peritoneal membrane [81, and the potential contributory
effect of glucose absorption to hyperglycemia, hyperinsulinemia,
hyperlipidemia and obesity [9, 10]. To solve these problems,
amino acids were introduced as alternative osmotic agents, and
these may also compensate for protein and amino acid losses and
for the inadequate intake of proteins [11], On the other hand,
amino acids absorbed from the dialysis fluid may inhibit the oral
intake of nutrients, thereby minimizing the positive effect on
nutrition of the amino acids absorbed; a similar effect may also be
produced by glucose absorbed from glucose-containing dialysis
fluids.
The influence of peritoneal dialysis solutions of varying com-
position and filling volumes on food intake was earlier examined
in studies on rabbits [12]. These studies showed that amino acids
and glucose have a non-specific inhibiting effect on food ingestion,
depending on the osmolality of the solution, and that large filling
volumes also inhibit food intake. However, no systematic studies
have been done to determine whether peritoneal dialysis fluids
that contain glucose or amino acids influence the oral intake of
specific nutrients (carbohydrate and proteins).
In the present investigation, we employed a recently introduced
experimental model for studies of the ingestive behavior in
conscious, free-moving rats with feeding catheters channeled from
the top of the skull to the oral cavity [13]. The aim of the
investigation was to study in normal rats how various intraperito-
neal (i.p.) filling volumes and various concentrations of glucose
and amino acids in the peritoneal dialysis (PD) fluid influence the
consumption of carbohydrate and protein solutions infused in-
traorally.
Methods
Animals
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Male Wistar rats (MollegArd Breeding Laboratory, Ejby, Den-
mark), weighing 300 to 350 g were maintained in an air-condi-
tioned temperature-controlled colony room in which the lights
were off between 12:00 and 24:00 hours. The rats had continuous
access to food and water.
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Operations
lntraoral cannulae were implanted from the top of the skull to
the oral cavity as described by Kaplan, Bender and Sodersten [13].
The animals were allowed a post-operative recovery period of
four weeks to overcome the metabolic effects of surgical trauma
and allow infections which sometimes exist around the catheter to
heal spontaneously. It is obviously important that the animals
should be free of infections, since these reduce the food intake.
Post-operative body wt was therefore recorded weekly and all the
animals used for the experiment had regained preoperative weight
by the time of the experiment.
Test of ingestive behavior
The pellets were removed at 07:00 hours and the animals were
tested for protein or sucrose ingestion six hours later, that is, one
hour after the lights were turned off. The pellets were replaced
after testing. Intake was measured by placing each animal in a
circular (35 cm in diameter) plexiglass arena. The rats had their
intraoral cannulae connected to a peristaltic pump (Alitea XV,
Ventur Alitea, Stockholm, Sweden) that delivers a solution con-
taining a nutrient (sucrose or protein) at 1 ml/min. This activates
ingestive behavior, which ends by the time the animal actively
rejects the solution or passively lets it drip from its mouth [14].
The infusion was interrupted for 30 seconds and then started
again. If the rat stopped ingesting either actively or passively
within one minute after re-starting the infusion, the test was
terminated. If not, the infusion was continued and again inter-
rupted for 30 seconds when the animal rejected the solution. This
procedure was repeated until the criterion, rejection of the
solution within one minute after a 30 seconds interruption of the
infusion, was fulfilled. Most rats stop ingesting the solution within
the first minutes after having rejected it once. The rats were
trained daily to ingest the intraoral diet solutions and the exper-
iments were performed after a stable level of intake was attained.
They were then studied once a day on consecutive days.
Intraoral diet solutions
Two different solutions were used, a carbohydrate solution
containing sucrose 342 g (1 M)Iliter and a protein solution
containing cascin 97 g/liter, representing the protein component
of Fortimel® (Nutricia Nordica AB, Stockholm, Sweden), a
solution used for enteral feeding. The solutions were prepared
before each daily test.
Peritoneal dialysis solutions
Glucose-based peritoneal dialysis (PD) solutions contained
13.6, 22.7 and 38.6 g/liter anhydrous glucose (Dianeal®, Baxter,
Castlebar, Ireland). The electrolyte concentrations were the same
in the three solutions: sodium 132, calcium 1.75, magnesium 0.75,
chloride 102 and lactate 35 mmol/liter. The osmolalities were 340,
390 and 480 mOsm/kg H20, respectively. Amino acid-based PD
solutions containing 11.0, 18.4 and 31.2 g/liter of amino acids were
prepared by diluting an amino acid solution for intravenous use
(Renamin® Clintec Nutrition Co., affiliated with Baxter Health-
care Co. and Nestle S.A.) in a solution with the same electrolyte
content as the glucose-based solution. The osmolalities of these
solutions were 341, 376 and 436 mOsm/kg H20. A solution with
the same electrolyte content but without glucose or amino acids
was used as a control in the experiments made to test the effect of
the PD solutions. The osmolality was 290 mOsm/kg H20.
Procedures
The PD solutions were given as intraperitoneal (i.p.) injections
in a dose of 30 ml, except in the experiments in which the effect of
the intraperitoneal filling volume was assessed. Twenty minutes
after the i.p. injection, the intraoral infusion of the diet solution
was started.
Effects of intraperitoneal filling volume on sucrose intake
Eight rats with a stable intraoral sucrose intake were injected
i.p. with 0, 10, 20, 30 and 40 ml of isotonic saline (0.9% NaCI) in
random order on consecutive days and the amount of their intake
of sucrose was then determined.
Effect of glucose-based PD solutions on intraoral sucrose or
protein intake
Two groups of rats, one with a stable intraoral sucrose intake
(N = 8) and one with a stable intraoral protein intake (N = 8)
were injected i.p. with 30 ml of control solution and solutions
containing 13.6, 22.7 and 38.6 g/liter of glucose in random order
and the amount of their intake of sucrose and protein, respec-
tively, was determined.
Effect of amino acid-based PD solutions on intraoral sucrose or
protein intake
Two groups of rats, one with a stable intraoral sucrose intake
(N = 8) and one with a stable protein intake (N = 8) were injected
i.p. with 30 ml of control solution and solutions containing 11.0,
18.4 and 31.2 g/liter of amino acids in random order and the
amount of their intake of sucrose and protein, respectively, was
determined.
Duration of appetite suppression
In five rats with a stable intraoral intake of sucrose solution,
sucrose ingestion was tested at different times after i.p. injection
of 30 ml PD solution containing glucose (38.6 g/liter). The
intraoral infusion of sucrose was started 30, 60, 120 and 180
minutes after the i.p. injection; the experiments were made on
consecutive days in random order. Similarly, in another group of
five rats with stable intraoral sucrose intake, the intake of sucrose
was tested 30, 60, 120 and 180 minutes after i.p. injection of 30 ml
solution containing amino acids (31.2 g/liter). Intake of sucrose
solution without i.p. injection of PD fluid was used as control in
each group.
Analysis of data
Data are presented as mean 5EM and analyzed using one-way
ANOVA followed by a paired t-test when the ANOVA test
showed significance (P < 0.05).
Results
Adaptation of ingestive behavior
Rats receiving intraoral sucrose solution ingested relatively
large amounts (13.5 0.8 ml) of the solution offered on the first
day of the intraoral infusion, Then they increased their intake
gradually before it stabilized at 18.8 0.9 ml on the fifth day (Fig.
1). Rats receiving protein, on the other hand, had a low intake (2.8
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Fig. 1. Daily ingestion of intraorally delivered diet solutions containing
sucrose 342 glliter (•), in 8 rats and protein 97glliter (0) in 8 rats during the
training period. Mean SEM.
Table 1. Ingestion of intraorally delivered sucrose solution (342 g/liter)
after i.p. injection of different volumes of 0.9% NaC1 solution
Saline volume
ml
Ingested volume of
sucrose solution ml
0 19.3 1.2
10 19.5 1.3
20 20.2 1.4
30 19.4 1.2
40 19.5 1.3
Eight rats received the different volumes of isotonic saline in random
order on successive days. Mean SEM.
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Fig. 2. Effect of intraperitoneal injections of 30 ml of PD solutions contain-
ing 13.6, 22.7 and 38.6 glliter glucose on ingestion of intraorally delivered
sucrose (342 glliter) solution in 6 rats (A) and intraorally delivered protein (97
glliter) solution in 6 rats (B). The solutions with varying glucose conentra-
tion were injected in random order on successive days. Mean SEM.
Ingestion after injection of the glucose solutions were statistically com-
pared with ingestion after injection of a control solution, which had the
same electrolyte content but contained no glucose. < 0.05, < 0.01,
< 0.001.
Intraperitoneal amino acid-based solutions
Intraperitoneal injections of 30 ml of amino acid-based solu-
tions containing 11.0, 18.4 and 31.2 g/liter of amino acids,
provided a total i.p. dose of 0.33, 0.68 and 0.93 g amino acids. The
sucrose ingestion was suppressed by 9.7%, 17.1% and 33.2%,
respectively (Fig. 3A), corresponding to a reduction of 0.66, 1.31
and 2.87 g in sucrose intake. The protein ingestion was suppressed
by 13.5%, 25.9% and 33.1%, respectively (Fig. 3B), corresponding
to a reduction of 0.52, 1.00 and 1.27 g in protein intake below the
control level, that is, at each dose level the suppression of protein
intake was higher than the dose of amino acids given i.p.
Duration of appetite suppression
The rats injected i.p. with 30 ml of PD solution containing
glucose (38.6 g/liter) and tested for the subsequent intake of
sucrose 30, 60, 120 and 180 minutes after i.p. injections had the
lowest sucrose intake after 30 minutes after injection and then a
gradual increase in intake over the following 150 minutes (Fig.
4A).
The rats injected i.p. with 30 ml of solution containing amino
acids (31.4 g/liter) and tested for the subsequent intake of sucrose
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0.6 ml) on the first day of intraoral infusion and then increased
their intake gradually over a longer period of time until it
stabilized at 39.8 0.8 ml on the ninth day (Fig. 1).
Influence of i.p. filling volume
Intraperitoneal injections of 0, 10, 20, 30 and 40 ml of isotonic
saline (0.9%) had no effect on sucrose ingestion, as demonstrated
in Table 1, and they had no effect on protein ingestion (data not
shown).
Intraperitoneal glucose-based PD solutions
Intraperitoneal injections of 30 ml of glucose-based PD solu-
tions containing 13.6, 22.7 and 38.6 g/liter glucose provided a total
i.p. dose of 0.41, 0.68 and 1.16 g glucose. The sucrose intake was
suppressed in a dose-dependent manner by 12.2%, 23.6% and
36.1%, respectively (Fig. 2A), corresponding to a reduction in
sucrose intake below the control level by 0.99, 2.58 and 3.74 g, that
is, at each dose level the suppression of the sucrose intake was
considerably higher than the dose of glucose given i.p. The
glucose-based PD solutions had no significant effect on protein
ingestion (Fig. 2B).
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Fig. 3. Effects of intraperitoneal injections of 30 ml of solutions containing
110, 18.4 and 31.2 g/liter on ingestion of intraorally delivered sucrose (342
g/liter) solution in 6 rats (A) and intraorally delivered protein (97 glliter)
solution in 6 rats (B). The various doses of amino acids were in each group
injected in random order on successive days. Ingestion after injection of
the glucose solutions were statistically compared with ingestion after
injection of a control solution, which had the same electrolyte content but
contained no glucose. < 0.05, < 0.01, ***p < 0.001.
30, 60, 120 and 180 minutes after i.p. injections, showed a
reduction in sucrose intake 30 minutes after injection followed by
a further decrese in intake over the following 150 minutes (Fig.
4B).
Discussion
In the present studies we assessed ingestive behavior quantita-
tively by measuring the consumption of orally infused nutritional
solutions in conscious, free-moving rats. This model has earlier
been used in neuropharmacological studies of appetite regulation
and has proved to be accurate and highly reproducible, especially
since the same group of animals can be studied repeatedly on
consecutive days and can serve as their own controls [13, 14]. A
training and adaptation period is required during which the intake
of the orally infused solution is gradually increased until a stable
intake level is attained. This adaptation period was considerably
longer with the protein solution than with the sucrose solution
(Fig. 1).
Abdominal distension by the dialysis fluid in the peritoneal
cavity has been thought to interfere with gastric emptying, possibly
resulting in impairment of food intake [15, 16]. However, we
Control 30 60 90 120 150 180
Fig. 4. Sucrose ingestion different times after intraperitoneal injection of 30
ml peritoneal dialysis solution containing glucose 38.6 glliter (5 rats) (A) or a
solution containing 31.2 g/liter amino acids (5 rats) (B). In each group
ingestion was measured at different times after injection in random order.
Mean SEM. Ingestion of sucrose solution without i.p. injection of PD
fluid was used as control in each group.
found in this study no suppression of food intake with peritoneal
filling volumes up to 40 ml, that is, more than 10 per cent of the
body wt of the rats. In accord with this, Hylander et a! found no
difference in intragastric pressure [17], and no difference in the
consumption of a standard meal in CAPD patients with and
without dialyzate [18]. Balaskas, Rodela and Oreopoulos [12], on
the other hand, reported that the food intake was significantly
suppressed by large filling volumes (10% of the body wt) in rabbits
studied over two to four weeks and that the effect was more
marked when the total osmolality was high. In rabbits receiving
four daily exchanges of dialysis solution (5% of body wt) contain-
ing either amino acids (2%) or glucose (1.5%), they also observed
that the food intake was similarly depressed by both solutions, but
it gradually returned towards control levels at the end of a
six-week period. The experiments by Balaskas et al differed from
our acute experiments in several respects: they extended over
several weeks, required surgical peritoneal catheter placement,
involved metabolic adaptation to the surgical trauma and were
performed in a different species.
Our results demonstrate that both glucose and amino acid-
containing peritoneal solutions have a dose-related inhibiting
effect on the oral intake of sucrose. However, in contrast to the
amino acid solutions the glucose solution did not suppress the
A
25
20 **
EjI L fln
Control 11 18 31
Amino acid concentration, g/liter
A
20
16
12
8
4
B
20
16
12
E
U)
11)C)
0
0
U)
a)
U)0
C.)
(I)
E
ii)
U)
a)0)C
C0
0in
ci)(I)0
I.)
(I)
C0—
o oU)ci)
CU)
a)
OC0
I I I
Control 30 60 90 120 150 180
1280 Mamoun et al: Ingestion and peritonal dialysate
intake of protein. This seems to rule out the view that the
inhibition of appetite was a nonspecific effect of the high osmo-
lality since, if this had been so, the glucose solutions might have
been expected to inhibit the oral intake not only of sucrose but
also of protein.
Considerable emphasis has been placed on the regulation of
food intake by circulating nutrients [19]. It is generally assumed
that there are various types of cells which sense the presence of
specific nutrients or respond to their rate of metabolism or
production of specific metabolites and that these cells are capable
of signaling this information to the region of the brain that
controls food intake [191. In addition, hormonal signals generated
by the gastrointestinal tract are sensed directly by the brain so that
changes in appetite and food intake occur. Thus, satiety is a result
of elevated levels of specific circulating nutrients and gastrointes-
tinal signals [19].
It has been reported that intraportal or intramesenteric infusion
of glucose suppresses feeding in fasting animals [20, 21], probably
because of signaling by hepatic glucoreceptors via the vagus nerve.
Moreover, elevated glucose levels cause an increase in plasma
insulin, which terminates feeding via insulin-sensitive cells in the
brain [22]. Our data showing that intraperitoneal glucose elicits
dose-dependent reduction of carbohydrate ingestion are in accor-
dance with previous reports.
In the cascade of gastrointestinal secretions following a meal,
the sulfated cholecystokinin octapeptide (CCK-8) is a physiolog-
ical satiety signal in the rat [23]. Recent studies by our group
demonstrate that CCK-8 inhibits the intake of carbohydrate, but
not protein [24, 25]. Our results, showing an inhibiting effect of i.p.
glucose on carbohydrate, but not on protein ingestion, may
suggest that the inhibiting effect is elicited by CCK-8, released in
response to glucose absorbed from the PD fluid. The lack of effect
of glucose on protein intake in our experiments may also be
related to the lowering effect by insulin on the plasma levels of
amino acids, which inhibit amino acid-related signals for protein
satiety.
Amino acids in peritoneal solutions were introduced with the
dual purpose of providing an alternative osmotic agent and giving
supplementary protein to patients with protein malnutrition [11].
Since chronic renal failure is associated with amino acids abnor-
malities that are not fully corrected by CAPD treatment [26], it
has been postulated that dialysis with amino acid solutions may
normalize the uptake of amino acids by the central nervous system
by inducing less marked stimulation of insulin secretion than with
glucose solutions and also by providing an increased supply of
branched-chain amino acids [27, 28].
There is evidence that protein intake, in addition to energy
intake, is directly involved in the regulation of feeding behavior
and that such regulation is sensitive to the amino acid composition
of the protein consumed [29, 30]. The amino acid supply from
dietary protein also controls brain metabolism by providing
specific amino acids (tryptophan, tyrosine), which are precursors
of major neurotransmitters (serotonin, catecholamines). Hence, it
has been proposed that amino acids act as significant components
of the control mechanism for protein and energy intake by
inducing appetite suppression through their effect on neurotrans-
mitter synthesis [31, 32]. Ingestion of a mixed protein, fat and
carbohydrate solution or a pure protein solution has been dem-
onstrated to cause a massive increase in plasma levels of CCK-8
[24, 25]. However, clinical studies of the effect of peritoneal
dialysis solutions containing amino acids on appetite have given
conflicting results, suggesting a decrease [33, 34], an increase [27,
35] or no change [28, 36].
Our data demonstrate that PD solutions with amino acids
suppressed both sucrose and protein ingestion in a dose-depen-
dent manner. The effect was relatively small (less than 10%
inhibition) with the lowest amino acid concentration (11 glliter),
that is, the concentration generally recommended for clinical use
[37].
It has been reported that rats given continuous infusions of
energy-containing nutrients reduced their daily food intake, but
that the reduction in oral energy intake was only about 40 to 80%
of the i.v. energy supply, the variation depending on the type of i.v.
nutrition [19, 38]. It was also observed that the oral intake of
energy could be further reduced to make it equal to the energy
infused, when insulin was coinfused [38]. Intraportal infusion of
glucose was also more efficient than i.v. infusion in suppressing
oral intake [22]. It should be emphasized that the aforementioned
experiments are not directly comparable to ours, since they were
performed during several days, while we have studied for the first
time the acute effect of nutrients given i.p. on the oral intake of
specified nutritional solutions given as a single meal.
We observed that the reduction in oral carbohydrate intake
after i.p. injection of PD fluids containing glucose was at each
glucose concentration more than twice as high as the total dose of
glucose injected i.p. Earlier studies have shown, that after i.p.
injection of glucose-containing PD fluid in rats, only about 50% of
the glucose dose is absorbed within the first 45 minutes [39], that
is, within the period when the appetite tests using oral carbohy-
drate feeding were finished. Hence, the reduction in sucrose
intake may in fact have been about four times higher than the
effective dose absorbed. Similarly, the amino acid-based solutions
reduced the intakes of both protein and sucrose by much larger
amounts than the doses of amino acids injected i.p. We speculate
that the high efficacy of appetite suppression elicited by the PD
solutions is related to the i.p. route of administration, resulting in
a rapid uptake of glucose or amino acids in the portal circulation,
which in turn resulted in high concentrations in the splanchnic
area, with subsequent stimulation of hepatic glucoreceptors and
secretion of CCK-8, insulin and other mediators of appetite
suppression.
We observed a maximum inhibitory effect of the 38.6 glliter
glucose solution on sucrose intake at 30 minutes after the
injection. The effect then gradually tapered off, but had not
reached the basal level at 180 minutes. In contrast, after intraper-
itoneal injection of the 31.2 g/liter amino acid solution, the
sucrose intake, which was reduced after 30 minutes, continued to
decrease over the following 150 minutes. CAPD patients exhibit a
peak in blood glucose concentration at 30 to 60 minutes after
instillation of glucose-based dialysis fluid, followed by a rapid fall
in the concentrations over the next two hours [40], while after
instillation of amino acid-based dialysis fluid, the peak concentra-
tions of plasma amino acids are attained at one to two hours and
then remain high over the next one to two hours [36, 41]. Hence,
it appears that the patterns of appetite suppression after i.p.
injections of glucose or amino acids in rats are similar to the
patterns of plasma concentration described for each compound
after instillation in CAPD patients. These results accord with the
view that inhibiting effects on appetite by i.p. glucose and amino
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acids, respectively, are mediated by the levels of the circulating
compounds.
In conclusion, our results indicate that the inhibition of appetite
caused by peritoneal solutions containing glucose or amino acids
seems to be specific for each nutritional constituent and not
simply an effect of hyperosmolality or large filling volumes.
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